HomeNewsNews
News

Delegation from International AIDS Vaccine Initiative (IAVI) Visited GIBH

Date：Feb 05, 2007

Prof. Seth Berkley, president of International AIDS Vaccine Initiative (IAVI) and his delegation paid a visit to Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences. They were accompanied by Prof. ZHANG Linqi, Director of AIDS Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College, and other four senior officials in the related areas.

In the symposium held with the investigators of GIBH, Prof. Berkley gave a detailed introduction of the history of IAVI and the latest research progress worldwide in AIDS vaccine. Right following his presentation, Prof. ZHANG Linqi, Prof. ZENG Yaoying, Director of Tissue Transplantation and Immunity Center, Ji Nan University, Prof. WU Youchang from School of Basic Medical Sciences, Sun Yat-sen University, Prof. TANG Xiaoping, president of Guangzhou No.8 People’s Hospital as well as Dr. CHEN Ling, and Dr. PENG Tao from GIBH respectively delivered wonderful speeches on diverse areas concerning AIDS vaccine. Director CHEN Ling further expressed his determination to work cooperatively with IAVI and other research institutions and clinical units, so as to establish an effective research team on AIDS vaccine in Guangzhou, as part of the international community making contributions to the public cause against AIDS.

President Berkley showed his gratitude and appreciation for the mini-symposium organized by our institute. Meanwhile he was surprised to find such an innovative research group for AIDS vaccine of an international level in Guangzhou.

The International AIDS Vaccine Initiative (IAVI) is a global non-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996 and operational in 27 countries, IAVI and its network of collaborators research and develop vaccine candidates. IAVI has so far invested more than US$100,000,000 in AIDS vaccine R&D, and is currently in charge of the second largest research project.